Naveen

Quick links to important sections

Naveen

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Naveen

Property Description
Active ingredient Chlormadinone Acetate, Ethinyl Estradiol
Form Oral tablets
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic (Steroidal hormones)
Status Prescription-only

Naveen: A Combined Hormonal Contraceptive

Naveen is fundamentally classified as a Prescription-only Combined Hormonal Contraceptive (CHC) medication, administered as oral tablets. This pharmaceutical preparation, often recognized by the INN combination of Chlormadinone Acetate and Ethinyl Estradiol, is a monophasic synthetic product containing a fixed amount of both hormonal components in each active tablet. The CHC class is clinically recognized for its high efficacy in regulating the female reproductive cycle and preventing conception.

Composition and Unique Antiandrogenic Progestin

The formulation relies on two active ingredients: Ethinyl Estradiol (EE), the estrogen, and Chlormadinone Acetate (CMA), the progestin. While many similar products exist, the specific choice of CMA, a progesterone derivative, is a key differentiating feature as it is well-documented for its antiandrogenic properties. This means that, unlike some non-antiandrogenic progestins, it actively works to oppose the effects of natural male-type hormones by functioning as an antagonist of the androgen receptor. This particular combination is characterized by its specific hormonal profile.

General Purpose of this Progestin-Estrogen Combination

The established and primary general purpose of this oral formulation is the highly effective prevention of pregnancy (contraception) in women of reproductive age. This action is typical for all combined oral contraceptives, achieved primarily through the inhibition of ovulation and alteration of cervical mucus. Beyond this essential function, the inherent antiandrogenic properties of the Chlormadinone Acetate component offer a supplementary general benefit by supporting hormonal balance, making it a distinct option for those seeking a combined oral pill with this specific ancillary characteristic.

What side effects are possible with Naveen?

The possible side effects and safety profile of this combined hormonal contraceptive are formally defined by authoritative government regulatory documents, utilizing the standard System-Organ-Class (SOC) structure and frequency categories.

Documented Adverse Reactions

The most frequently documented adverse reactions, classified as Common (ge 1/100 to <1/10), often involve systemic effects such as headache, nausea, breast pain or tenderness, weight gain, and depressed or altered mood. Uncommon effects (ge 1/1000 to <1/100) may include diarrhea, vomiting, migraine, and fluid retention. The label classifies serious complications separately, regardless of frequency.

Serious Safety Risks

The regulatory label for this class of medicine highlights rare but critical safety risks, most notably Venous Thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism (ATE), including stroke and myocardial infarction. Other serious documented risks include the development of Hepatic Neoplasms (liver tumors) and significant, sustained hypertension.

Safety Constraints and Considerations

Safety-Related Restrictions formally contraindicate use in individuals with a history of or current diagnosis of thromboembolic disorders or severe hepatic disease. Population-specific safety notes state that use is not generally recommended for smokers over age 35 due to a substantially increased risk of serious cardiovascular events. Time-related patterns documented in the label indicate that breakthrough bleeding or spotting is common during the first few months of use and that the highest excess risk of VTE is observed during the first year of use.

Regulatory Structure

This structure ensures that patients and healthcare providers can differentiate between common, typically non-serious, effects and the rare, but life-threatening, vascular events inherent to the combined hormonal contraceptive class, strictly based on risk data defined by regulatory authorities.

Overdose and Emergency Response

Official regulatory guidance for combined hormonal contraceptives classifies the acute toxicity following large-dose ingestion as low, and severe, life-threatening outcomes are generally considered unlikely. The officially documented clinical manifestations of overdose primarily affect the gastrointestinal and reproductive systems. Symptoms commonly include nausea, vomiting, and breast tenderness. A key manifestation noted in regulatory summaries is the occurrence of vaginal bleeding, specifically withdrawal bleeding or spotting, which may present 2 to 7 days after the overdose event.

Regulators consistently state that immediate medical help must be sought right away for any suspected overdose. This mandate is driven by the low but inherent, class-specific risk of serious complications, particularly the potential for thromboembolic events (blood clots), which necessitates urgent evaluation and monitoring. If symptoms such as sudden chest pain, difficulty breathing, or severe leg swelling are observed, contact emergency services immediately.

Management of this type of overdose is strictly symptomatic and supportive as dictated by official prescribing information. No specific antidote is known to exist. Required procedural steps include monitoring of vital signs, such as temperature, pulse, and blood pressure. Withdrawal bleeding as an overdose consequence is a specific consideration for female pediatric patients who have reached menarche.

Therapeutic Uses of Naveen

The combined hormonal contraceptive pill containing chlormadinone acetate and ethinyl estradiol is used to address several core therapeutic domains.

The medication is primarily applied for contraception and reproductive control. It is also commonly applied across domains where additional symptomatic support is needed, particularly for issues related to systemic imbalance.

“It is commonly used across conditions presenting with episodic or fluctuating symptom patterns of the menstrual cycle.”

The medication is relevant for easing symptoms related to systemic imbalance, including conditions presenting with recurrent manifestations like acne vulgaris, oily skin (seborrhea), excessive hair growth (hirsutism), and gynecological symptoms such as dysmenorrhea (painful periods) and heavy menstrual bleeding. This supportive therapeutic benefit provides assistance with functional stability when symptoms interfere with routine activities.


Quick Fact: Support for Menstrual Symptoms

The formulation supports the patient during difficult episodes by easing distress associated with menstrual cramping and helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Naveen is officially indicated for use in women of reproductive age who require combined hormonal contraception and who have already reached menarche.

Populations for whom use is Contraindicated

The medicine is strictly contraindicated by regulatory documents in women with several pre-existing conditions, primarily those related to cardiovascular and hepatic risk:

  • A current or past history of venous thromboembolism (VTE) (e.g., deep vein thrombosis, pulmonary embolism) or arterial thromboembolism (ATE) (e.g., stroke, myocardial infarction).
  • Known or suspected pregnancy or undiagnosed genital bleeding.
  • Severe hepatic disease until liver function has fully normalized, or any current or past liver tumors (benign or malignant).
  • Known or suspected hormone-sensitive malignancies, such as breast cancer.
  • A history of migraine with focal neurological symptoms (aura).

Age and Physiological Restrictions

Population Regulatory Status
Pre-Menarcheal Females Not applicable/indicated
Adolescents under 16 Safety and efficacy not established
Post-Menopausal Women Not indicated
Lactating/Breastfeeding Not recommended

Eligibility is also prohibited in women who are over 35 years of age and smoke, or who have specific metabolic conditions such as severe dyslipoproteinaemia.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The documented interaction profile for Naveen is defined by two primary regulatory concerns: mandatory prohibitions and pharmacokinetic changes that affect drug exposure.

Contraindicated Combinations

Naveen is formally contraindicated for co-administration with specific drug regimens used to treat Hepatitis C Virus (HCV) infection. These specific regimens include combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, or combinations containing glecaprevir/pibrentasvir. This restriction is based on the documented risk of significant liver enzyme (ALT) elevations. Patients must cease using Naveen prior to starting these specific antiviral therapies, and the contraceptive can be restarted two weeks following the completion of the treatment course.

Pharmacokinetic Interactions

The metabolism of both Ethinyl Estradiol and Chlormadinone Acetate is susceptible to interaction with CYP450 enzyme inducers. Medicinal products or herbal products (such as St. John’s Wort) that accelerate the activity of these enzymes lead to increased clearance of the contraceptive hormones. This pharmacokinetic effect results in reduced plasma concentrations, potentially compromising effectiveness. Due to this official risk, regulatory guidelines require the use of an alternative, non-hormonal contraceptive method during co-administration with an enzyme-inducing substance and for a period of 28 days after its discontinuation. Conversely, Naveen may also cause increased plasma levels of certain co-administered drugs that are sensitive CYP1A2 substrates.

Mechanism of Action

How Naveen Works at the Biological Level

The action of Naveen is primarily centered on dual agonism, meaning it functions as an activator for two distinct receptor systems: the Alpha-1 (alpha1) Adrenoceptors and the Dopamine-2 (D2) Receptors. This simultaneous engagement of adrenergic and dopaminergic signaling defines the drug's overall mechanism and its resulting physiological consequences.

Targeting Adrenergic Receptors for Vascular Control

Naveen acts as an agonist on peripheral alpha1 adrenoceptors, initiating a Gq-protein coupled cascade within vascular smooth muscle cells. This process causes a sustained increase in intracellular calcium ions. This alpha1-mediated mechanism leads directly to vasoconstriction and a resultant increase in systemic vascular resistance. This domain is essential for the drug’s physiological effect of achieving elevated arterial blood pressure.

Modulating Dopaminergic and Central Pathways

The drug's D2 agonism modulates signaling both centrally and peripherally. In the central nervous system, this mechanism affects pathways governing motor function and neuroendocrine activity. Peripherally, D2 activation in the kidney acts to suppress renin release, a process that modulates activity within the renin-angiotensin-aldosterone system (RAAS).

Dosage and Administration Information

Instruction Map: How to use Naveen

Instruction Detail
Route of administration Oral use only; tablets are to be swallowed whole.
Dosing schedule One active tablet containing 2 mg Chlormadinone Acetate and 0.03 mg Ethinyl Estradiol is taken daily.
Frequency pattern Daily in 28-day cycles (21 active tablets followed by 7 tablet-free days).
Timing in relation to meals (if applicable) May be administered without regard to meals.
Special procedural conditions Intake must adhere strictly to the sequential order printed on the blister pack. Non-hormonal backup is required if the first cycle is initiated later than Day 1 of the menstrual cycle.

Missed-Dose Rules

The protocol for managing a missed dose depends on the time elapsed. If the scheduled intake is delayed by less than 12 hours, the tablet is taken immediately, and the schedule continues as usual. If the delay exceeds 12 hours, the tablet is still taken immediately, but additional non-hormonal contraception must be used for the subsequent seven days.

Connection to the Overall Use Protocol

The instructions define a 28-day cyclic protocol that requires precise, uninterrupted daily tablet intake. Adherence to the sequential order and the time-dependent missed-dose procedures are the core procedural elements that govern the standardized use of the medication.

Recent Clinical Evidence

Naveen: Recent Clinical Evidence


Evidence for Use in Episodic Conditions

Naveen was evaluated in individuals with conditions characterized by fluctuating or episodic manifestations. Studies explored how symptoms evolved in the observed populations during these episodic manifestations. Research describes patterns observed related to outcomes capturing phases of heightened symptom activity in some groups. Specifically, studies monitored measured changes during the study period for outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states.

A key limitation is that data are still emerging, and certainty remains low for many subgroups. While studies focused on research exploring short-term symptom changes, the follow-up durations were limited. Therefore, long-term effects are not fully established regarding the frequency or severity of future episodic manifestations.


Evaluation of Daily Functioning Outcomes

Research explored Naveen in relation to outcomes reflecting daily functioning or activity level. These were applied in studies examining patient-reported experiences to understand how people managed their day-to-day life. The data describes patterns observed in patient-reported outcomes describing perceived discomfort. Findings from large studies describe patterns observed in the overall population where some individuals may report changes in their overall activity level.

However, several research limitations exist. Since these studies were primarily used in observational settings evaluating daily-life functioning, results apply only to the populations studied. The evidence contributes to the broader evidence landscape, but do not determine whether an individual will respond similarly when it comes to long-term outcomes related to systemic or functional imbalance.


Research in Younger Populations

Naveen was evaluated in special populations, particularly adolescents and young adults. Studies monitored short-term changes observed in some studies of individuals in this group, though the sample sizes were modest. The subgroup findings are uncertain because the data collected for this age group appears to be limited in terms of duration and scope.

Frequently Asked Questions (FAQ)

Common questions about Naveen (FAQ)


Q: Does Naveen cause tiredness or make you drowsy?

Official safety data for this medication class lists effects like headache and migraine as commonly or uncommonly reported. However, regulatory documents do not specifically list tiredness, drowsiness, or fatigue as frequently observed side effects for this medication.


Q: Does alcohol interact with Naveen?

Regulatory documents generally do not list a direct chemical interaction between alcohol and this combined hormonal contraceptive. General guidance suggests that any vomiting occurring shortly after use may affect the absorption of the tablet.


Q: Can you take over-the-counter pain relievers while using Naveen?

Official safety information for this class of medicine focuses on interactions with specific enzyme-accelerating products. Official regulatory documents do not specify prohibitions against all common over-the-counter pain medications, but safety information regarding cardiovascular risks should be kept in awareness.


Q: What happens if you miss using Naveen?

The official protocol documented by regulatory bodies requires that any missed tablet be taken immediately. If the scheduled intake is delayed by more than 12 hours, the regulatory instructions specify that a supplementary, non-hormonal contraceptive method must be used for the following seven days to help ensure continued effectiveness.


Q: Is it safe to take Naveen with high blood pressure medication?

Regulatory warnings indicate that significant, sustained high blood pressure is a serious risk factor associated with this class of medicine. Therefore, its use is formally contraindicated if high blood pressure is uncontrolled. Official regulatory documents do not list specific restrictions for co-administration when hypertension is under medical management.


Q: Can Naveen cause changes in mood or behavior?

Yes, official safety documents for this product list depressed or altered mood as a commonly documented adverse reaction. This is provided as factual information from clinical surveillance data.


Q: How quickly does Naveen start to work after the first use?

According to regulatory instructions, if the medication is started later than the first day of the menstrual cycle, a non-hormonal backup method is required. The need for a backup method indicates that contraceptive protection is not considered immediate upon initiation.


Q: What is the general consensus on Naveen's role in treatment?

Naveen is officially classified as a Combined Hormonal Contraceptive, and its established role is the prevention of pregnancy. The key component noted in official pharmacological documents is the progestin Chlormadinone Acetate, which also has documented antiandrogenic properties.


Q: Why is the research evidence for Naveen still ongoing?

Continuous monitoring and long-term studies are a standard requirement for all medicines, known as post-market surveillance. Research summaries indicate that data are still emerging, particularly regarding the long-term effects related to the frequency or severity of future episodic manifestations.


Q: Does Naveen interact with herbal supplements?

The official interaction profile specifically notes a concern regarding herbal products that accelerate certain liver enzymes, such as St. John’s Wort. These substances can potentially lead to reduced plasma concentrations of the hormones, which could compromise the medication's effectiveness.


Q: How does Naveen differ from other medicines that treat the same condition?

Naveen is a Combined Hormonal Contraceptive. It contains the progestin Chlormadinone Acetate, which official pharmacological documents note is documented for its antiandrogenic properties that oppose the effects of male-type hormones.


Q: Is Naveen the same as [Name of a known similar drug]?

Naveen is a Combined Hormonal Contraceptive containing a fixed dose of Chlormadinone Acetate and Ethinyl Estradiol. While other medicines belong to the same pharmacological class, Naveen contains the specific progestin Chlormadinone Acetate, as noted in the official composition.


Q: Are there any specific foods or drinks to avoid while taking Naveen?

Regulatory guidance states that the medication may be administered without regard to meals. Generally, there are no specific food restrictions documented in the product's official instructions.


Q: Is Naveen something I have to take every day?

Yes, the official instructions define a protocol that requires precise and uninterrupted daily tablet intake in a sequential 28-day cycle to ensure the medication maintains its contraceptive effectiveness.


Q: What happens if Naveen is used for a long time?

Regulatory documents indicate that the highest risk of serious events like Venous Thromboembolism (VTE) is observed during the first year of use. For long-term continuous use, regulatory agencies note the benefits of contraception should be considered alongside the risks, which require regular assessment.


Q: Why do some patients stop using Naveen?

Official regulatory documents indicate that use of the medication must be ceased if a patient develops any of the pre-existing conditions listed as formal contraindications. Discontinuation can also occur if a patient experiences and chooses to stop due to common side effects such as headache, nausea, or altered mood.


Q: Is Naveen a controlled substance?

No, Naveen is not classified as a controlled substance by official government drug authorities.


Q: Why are there different versions or strengths of Naveen?

Official regulatory information indicates the medication is a monophasic product. This means that each active tablet contains a fixed, uniform amount of its two hormonal components, Chlormadinone Acetate and Ethinyl Estradiol.


Q: Do you need a special prescription for Naveen?

Naveen is officially classified by regulatory bodies as a prescription-only medicine (POM). No regulatory source indicates that a 'special' type of prescription is required beyond what is standard for other prescription-only drugs.


Q: What is the goal of Naveen to cure the condition?

The goal of Naveen, as stated in its official indication by regulatory authorities, is the prevention of pregnancy (contraception). It is not indicated for the cure of any underlying medical condition.


Q: Are the side effects common or rare?

Official documents categorize effects into frequency brackets. For example, common effects include headache and nausea, while less frequent (uncommon) effects include diarrhea and vomiting. Serious safety risks, such as blood clots, are classified as rare but critical risks.


Q: Is there any information about Naveen in patients with mental health conditions?

Official safety documents list depressed or altered mood as a common adverse reaction for this product. Broader authoritative health guidelines for combined hormonal contraceptives generally provide informational context for use in individuals with common depressive disorders.

How should Naveen be stored and disposed of?

Official Storage Conditions

The combined hormonal contraceptive tablets must be stored strictly according to the conditions outlined in the official regulatory documents to protect the stability and potency of the active ingredients (Chlormadinone Acetate and Ethinyl Estradiol).

  • Temperature: Store the tablets at a temperature below 30 C [EMA SmPC]. Excessive heat and high temperatures must be avoided.
  • Protection: The medicine must be kept in its original package (blister pack and outer carton) to protect it from light and moisture [EMA SmPC].
  • Child Safety: All medications, including Naveen, must be stored out of the sight and reach of children [NIH MedlinePlus].

Disposal Requirements

Unused or expired medication must be handled as pharmaceutical waste and discarded safely:

  • Method: Disposal should occur through a designated drug take-back program or as directed by local regulations [FDA].
  • Restriction: The product must not be thrown away via wastewater (such as flushing) or ordinary household waste [EMA SmPC].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Naveen found in:

A-Z Index: